Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$1.75B+62.87%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vincent C. Tizzio
- Sector
- Financial Services
- Industry
- Insurance - Diversified
- Employees
- 1,966
- Beta
- 0.49
- Country
- BM
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 0.82
Financials
Revenue
$1.75B+62.9%Net Income
$383.28M+105.4%EBITDA
$338.00M+55.5%Free Cash Flow
$477.10M+135.3%EPS (diluted)
$5.06+158.2%Shares Outstanding (diluted)
74.20M-17.9%Operating Expenses
$481.16MCash & Debt
$6.09BReturn of Capital
$80.41MRevenue by Segment (annual)
$5.71BDividend per Share
$0.44Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.56B | $1.01B | $12.52 |
| 2024 | $6.02B | $1.08B | $12.49 |
| 2023 | $5.59B | $376.29M | $4.06 |
| 2022 | $5.30B | $223.08M | $2.27 |
| 2021 | $5.32B | $618.61M | $6.95 |
| 2020 | $4.76B | $-120.42M | $-1.79 |
| 2019 | $5.19B | $323.47M | $3.37 |
| 2018 | $5.12B | $43.02M | $0.52 |
| 2017 | $4.44B | $-368.97M | $-4.39 |
| 2016 | $4.13B | $513.37M | $5.13 |
| 2015 | $4.23B | $641.63M | $6.10 |
| 2014 | $4.45B | $810.75M | $7.38 |
| 2013 | $4.17B | $727.47M | $6.02 |
| 2012 | $3.90B | $547.24M | $4.05 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AXS's reported EPS growth of 9.1% a year over 13 years.
- EPS in 5 years
- $19.94
- Implied price
- $179.49
- Return from $95.62
- 13.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $89.24 — -6.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -0.9% | -8.4% | -2.0% | 3.0% | 7.2% | 10.9% |
| 4.1% | -3.8% | 2.9% | 8.2% | 12.7% | 16.5% |
| 9.1% | 0.8% | 7.9% | 13.4% | 18.1% | 22.1% |
| 14.1% | 5.5% | 12.8% | 18.6% | 23.5% | 27.7% |
| 19.1% | 10.1% | 17.7% | 23.8% | 28.9% | 33.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+33.33%Social Signal Score
Mentions (6)
- Newszacks.com·3d ago·Neutral
AXIS Capital's Specialty Focus Supports Growth and Shareholder Returns AXS' specialty focus, disciplined underwriting and rising investment yields support growth, while catastrophe and geopolitical risks remain key considerations.
View source ↗ - Newsbusinesswire.com·11d ago·Neutral
AXS and Denver Arts & Venues Launch Beyond AXS Community Initiative in Denver DENVER--(BUSINESS WIRE)--AXS and Denver Arts & Venues Launch Beyond AXS Community Initiative in Denver.
View source ↗ - Newszacks.com·34d ago·Neutral
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
View source ↗ - Newsglobenewswire.com·36d ago·Neutral
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active…
View source ↗ - Newsseekingalpha.com·53d ago·Neutral
AXS PFD E Offers Competitive Yield Versus Other Insurance Companies AXIS Capital Holdings Limited offers diversified specialty insurance and reinsurance, with strong A+ credit ratings and a BBB-rated preferred stock AXS.PR.E. AXS reported 15% YOY growth in both premiums written and diluted book value, with a solid 93.1% combined ratio, though reinsurance premiums declined 25%. The fixed-rate, non-cumulative Series E preferred AXS.PR.E offers QDI-eligible dividends and BBB credit quality, appeali…
View source ↗ - Newszacks.com·54d ago·Negative
AXS Lags Industry, Trades at a Discount: Here's How to Play the Stock AXIS Capital's specialty focus, premium growth and capital returns support growth, while catastrophe losses and competition pressure on underwriting margins.
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $2.81 per share
Typical surprise +10.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$2.84 vs $3.25miss
- Wed, Apr 29$3.42 vs $3.33beat
- Wed, Jan 28$3.25 vs $2.97beat
- Wed, Oct 29$3.25 vs $2.72beat
- Tue, Jul 29$3.29 vs $2.88beat
- Wed, Apr 30$3.17 vs $2.64beat
Estimates and results for AXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AXS officers and directors.
- Bought
- $854k
- Sold
- $639.7m
4 trades
9 trades
- Smith Henry Bsold
- Davis Charles Asold
- Smith Henry Bsold
- Draper Daniel Jsold
- Draper Daniel Jsold
- Draper Daniel Jsold
- Davis Charles Asold
- Davis Charles Asold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Feb 2, 2023 (22d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Feb 3, 2022 (16d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Jul 6, 2021 (32d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 17, 2021 (312d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Aug 4, 2020 (26d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.